Proteins and Peptides

04 Nov 2016 Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
04 Nov 2016 Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis
02 Nov 2016 Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Efficacy, Safety, and Stability in Animal Models
02 Nov 2016 Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Disorder
28 Oct 2016 The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin
27 Oct 2016 amcure Initiates Clinical Study in Patients to Test Novel Approach for Treating Advanced and Metastatic Cancers
26 Oct 2016 National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
26 Oct 2016 Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout
26 Oct 2016 Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label
26 Oct 2016 EVARREST® Fibrin Sealant Patch Gains FDA Approval on Expanded Indication for General Hemostasis
26 Oct 2016 ProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial
26 Oct 2016 Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves’ Disease
25 Oct 2016 Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound Care
25 Oct 2016 Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease
25 Oct 2016 Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Patients Hospitalized With Congestive Heart Failure
24 Oct 2016 Alphamab Starts Clinical Trial on Its First Novel Biologics KN015, a Long-acting FSH, for In Vitro Fertilization (IVF)
21 Oct 2016 FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray)
20 Oct 2016 RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
20 Oct 2016 Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection
17 Oct 2016 Ferring receives positive CHMP opinion for REKOVELLE® (follitropin delta)
16 Oct 2016 Abicipar Pegol PALM Study Phase 2 Data in Diabetic Macular Edema (DME) Presented at 2016 AAO Annual Meeting
13 Oct 2016 Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
13 Oct 2016 NeuroVive discontinues development of CicloMulsion for acute kidney injury
11 Oct 2016 Hansa Medical: First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)
09 Oct 2016 Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top